Archive | Clinical Trials

Idera’s tilsotolimod shows positive effect in mid-stage melanoma study

Idera Pharmaceuticals (IDRA -2.4%) announces final results from a Phase 1/2 clinical trial, ILLUMINATE-204, evaluating Toll-like receptor 9 (TLR9) agonist tilsotolimod, combined with Bristol-Myers Squibb’s (BMY -1.4%) Yervoy (ipilimumab), in metastatic melanoma patients.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

On-off dosing of cancer drugs does not help melanoma patients

Drugs that home in on and block cell growth signals can dramatically shrink tumors, but all too often the cancer comes back. An attention-grabbing mouse study 7 years ago suggested these targeted drugs would work better at shrinking melanoma tumors if cancer patients got a break from their medicine every few weeks.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Alternative pembrolizumab dosing schedule safe, effective in metastatic melanoma

Source: Healio, April 2020 An alternative pembrolizumab dosing regimen of 400 mg every 6 weeks appeared safe and effective for patients with metastatic melanoma, according to first clinical outcomes data from KEYNOTE-555 cohort B presented at the virtual American Association for Cancer Research Annual Meeting. “Pembrolizumab [Keytruda, Merck] is approved globally in multiple cancer indications […]

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers

An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors is expanding to include people with melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials